Search

everythinglearnresearchcommunity

for

Search:↓

Stem cell plasticity is crucial for wound healing but can also contribute to cancer development.

Cancer therapy can cause various skin problems, including hair loss, skin darkening, painful hand-foot syndrome, and severe skin damage.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

Cancer can hijack the body's cell repair system to promote tumor growth, and targeting this process may improve cancer treatments.

Cancer development is like natural selection, involving mutated cells and environmental factors.

TGFβ's manipulation of inflammation and immune cells affects cancer spread, suggesting new treatment strategies and biomarkers.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

Photobiomodulation therapy helps manage cancer treatment side effects but needs more research for optimization.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Early balding at 40 increases prostate cancer risk.

Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Hormone therapy affects cancer risks in transgender individuals differently than in cisgender people, and more research is needed to understand these risks and improve cancer screening guidelines.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Finasteride use is not clearly linked to an increased risk of male breast cancer.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Oncologists should better understand the unique impact of hair loss on Black breast cancer patients to offer more compassionate care.

Less differentiated melanoma cells are more vulnerable to a type of cell death, which could improve cancer treatments.

The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

The book concludes that despite progress, cancer drug treatments have not met the expectations set in the 1960s and 1970s.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Low zinc levels may be linked to the return of gynecologic cancers.